Compare Enveric Biosciences Inc (ENVB) vs Manulife Financial Corporation (MFC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs Manulife Financial Corporation — how do they compare? Enveric Biosciences Inc trades at $1.51 (market cap $6.69M), while Manulife Financial Corporation trades at $43.58 (market cap $69.26B). The key difference: Manulife Financial Corporation is far larger — about 10352.8× Enveric Biosciences Inc's market cap, and Manulife Financial Corporation pays a 3.27% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Enveric Biosciences Inc for 14 Days and Manulife Financial Corporation for 119 Days on average.
| ENVB | MFC | |
|---|---|---|
Market Cap | $6.69M | $69.26B |
Volume | 41,141 | 1,347,387 |
Sector | Health | Financials |
52-Week High | $10.80 | $44.77 |
52-Week Low | $1.27 | $31.64 |
Typical Hold Time | 14 Days | 119 Days |
Enterprise Value | -$1.60M | $64.51B |
Dividend Yield | — | 3.27% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.495, up 1.7% on the day, but technical indicators signal a bearish trend with moving averages and ADX pointing lower. The company reported no revenue in 2025 and a net loss of $8.77 million, though it has consistently beaten EPS expectations. Recent news includes a new U.S. patent allowance for its non-hallucinogenic mescaline derivatives and participation in an investment conference.
The outlook remains speculative given the lack of revenue and negative profitability, but analyst consensus is bullish with 75% buy ratings. Key risks include the pre-revenue biotech model and dependence on successful drug development. Upside potential hinges on clinical progress and regulatory milestones for its psychiatric therapeutics pipeline.
Manulife Financial (MFC) trades at $42.12, down 1.89% today, with a bearish technical outlook despite strong fundamentals. The company reported solid Q2 2026 earnings of $0.79 per share, beating expectations, with revenue growth to $53.01 billion in 2025 and improving cash flow trends. Recent institutional investments from Bank of America and others highlight confidence, while analyst consensus remains positive with 57% buy ratings.
MFC presents a mixed outlook: strong operational performance and dividend yield support upside, but technical indicators signal near-term pressure. Key risks include debt levels and market volatility, while opportunities lie in Asia growth and reinsurance deals. The stock trades above the consensus price target of $34.24, suggesting cautious optimism with execution-dependent returns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About Manulife Financial Corporation
Manulife provides life insurance and wealth management products and services to individuals and group customers in Canada, the United States, and Asia. Manulife is one of Canada's Big Three Life Insurance companies (the other two are Sun Life and Great West Life). As of Dec. 31, 2021, Manulife reported assets under management or administration of about CAD $1.4 trillion.
Read more on MFC →
